These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23561997)

  • 1. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 2. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 3. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense technology to lower LDL cholesterol.
    Neely RD; Bassendine MF
    Lancet; 2010 Mar; 375(9719):959-61. PubMed ID: 20227757
    [No Abstract]   [Full Text] [Related]  

  • 5. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 7. [Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B].
    Alonso R; Mata P; Alonso Y Gregorio M; de Andrés R
    Med Clin (Barc); 2015 Sep; 145(5):229-30. PubMed ID: 25543225
    [No Abstract]   [Full Text] [Related]  

  • 8. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hypercholesterolaemia: new treatment options.
    Ezzahti M; Sijbrands EJ; Mulder MT; Roeters van Lennep JE
    Neth J Med; 2013 Jun; 71(5):227-33. PubMed ID: 23799308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomitapide.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):179-81. PubMed ID: 25702706
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia.
    Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M
    Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
    Marbach JA; Thapa J; Goldenberg E; Duffy D
    Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. For patients who inherit homozygous familial hypercholesterolemia, 2 new treatments available.
    Morrow T
    Manag Care; 2013 Mar; 22(3):47-8. PubMed ID: 23610808
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering treatment for homozygous familial hypercholesterolaemia--authors' reply.
    Cuchel M; Rader DJ
    Lancet; 2013 Apr; 381(9873):1183. PubMed ID: 23561998
    [No Abstract]   [Full Text] [Related]  

  • 17. Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043021
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.
    Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M
    J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.
    Agarwala A; Jones P; Nambi V
    Curr Atheroscler Rep; 2015 Jan; 17(1):467. PubMed ID: 25398643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies for treating familial hypercholesterolemia.
    Bandeali SJ; Daye J; Virani SS
    Curr Atheroscler Rep; 2014 Jan; 16(1):382. PubMed ID: 24293346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.